Molecular basis and clinical management of Pompe disease
Pompe disease (glycogenosis type II) is a rare autosomal recessive lysosomal storage disorder due to mutations of the <em>GAA</em> gene, leading to the deficiency of acid α-glucosidase and consequent glycogen storage in various tissues, mainly in the skeletal muscle, heart and...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2013-02-01
|
Series: | Cardiogenetics |
Subjects: | |
Online Access: | http://www.pagepressjournals.org/index.php/cardiogen/article/view/905 |
id |
doaj-fd641ed5d0d84b90aff8023d526e046c |
---|---|
record_format |
Article |
spelling |
doaj-fd641ed5d0d84b90aff8023d526e046c2021-01-02T09:07:40ZengMDPI AGCardiogenetics2035-82532035-81482013-02-0131Se5e510.4081/cardiogenetics.2013.s1.e5968Molecular basis and clinical management of Pompe diseaseGiancarlo Parenti0Giuseppe Di Iorio1Simone Sampaolo2Giuseppe Fiorentino3Vincenzo Farina4Simona Fecarotta5Fabio Valente6Serena Ascione7Mario Caputi8Generoso Andria9Department of Translational Medical Sciences, Federico II University; Telethon Institute of Genetics and Medicine, NaplesDepartment of Neurology, Second University of NaplesDepartment of Neurology, Second University of NaplesRespiratory Disease Pathophysiology and Rehabilitation Unit, Monaldi Hospital, AO Colli, Second University of NaplesDepartment of Pediatrics, Paediatric Cardiology, Federico II University, NaplesDepartment of Translational Medical Sciences, Federico II University, NaplesCardiology Unit, Monaldi Hospital, AO Colli, Second University of NaplesDepartment of Translational Medical Sciences, Federico II University, NaplesRespiratory Disease Pathophysiology and Rehabilitation Unit, Monaldi Hospital, AO Colli, Second University of NaplesDepartment of Translational Medical Sciences, Federico II University, NaplesPompe disease (glycogenosis type II) is a rare autosomal recessive lysosomal storage disorder due to mutations of the <em>GAA</em> gene, leading to the deficiency of acid α-glucosidase and consequent glycogen storage in various tissues, mainly in the skeletal muscle, heart and liver. The consequent clinical picture is mainly due to the muscle and heart involvement, although clinical manifestations may be multi-systemic. The phenotype of patients is heterogeneous and the severity is inversely related to the residual enzymatic activity of acid α-glucosidase. More than 200 different mutations of <em>GAA</em> gene have been described and genotype/phenotype correlations have been established for some of them. Traditionally three forms have been described, <em>i.e. </em>early onset <em>classical</em> and <em>non-classical</em> forms and late onset attenuated forms. A severe hypertrophic cardiomyopathy in combination with conduction disorder in newborns represents a typical feature in the classic infantile presentation, while clinical picture in late onset forms is dominated by skeletal muscle dysfunction, resulting in mobility and respiratory problems. Enzyme replacement therapy with recombinant human GAA is the approved therapeutic approach in Pompe disease patients. Clinical trials on enzyme replacement therapy (ERT) support the efficacy in improving survival and hypertrophic cardiomyopathy, while efficacy seems to be variable on manifestations due to skeletal muscle involvement, mainly in lateonset patients. Considering the limitations of ERT and its high costs, innovative therapeutic approaches are now under development.http://www.pagepressjournals.org/index.php/cardiogen/article/view/905Pompe disease, glycogen storage disease type II, acid a-glucosidase, acid maltase, metabolic myopathy. |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Giancarlo Parenti Giuseppe Di Iorio Simone Sampaolo Giuseppe Fiorentino Vincenzo Farina Simona Fecarotta Fabio Valente Serena Ascione Mario Caputi Generoso Andria |
spellingShingle |
Giancarlo Parenti Giuseppe Di Iorio Simone Sampaolo Giuseppe Fiorentino Vincenzo Farina Simona Fecarotta Fabio Valente Serena Ascione Mario Caputi Generoso Andria Molecular basis and clinical management of Pompe disease Cardiogenetics Pompe disease, glycogen storage disease type II, acid a-glucosidase, acid maltase, metabolic myopathy. |
author_facet |
Giancarlo Parenti Giuseppe Di Iorio Simone Sampaolo Giuseppe Fiorentino Vincenzo Farina Simona Fecarotta Fabio Valente Serena Ascione Mario Caputi Generoso Andria |
author_sort |
Giancarlo Parenti |
title |
Molecular basis and clinical management of Pompe disease |
title_short |
Molecular basis and clinical management of Pompe disease |
title_full |
Molecular basis and clinical management of Pompe disease |
title_fullStr |
Molecular basis and clinical management of Pompe disease |
title_full_unstemmed |
Molecular basis and clinical management of Pompe disease |
title_sort |
molecular basis and clinical management of pompe disease |
publisher |
MDPI AG |
series |
Cardiogenetics |
issn |
2035-8253 2035-8148 |
publishDate |
2013-02-01 |
description |
Pompe disease (glycogenosis type II) is a rare autosomal recessive lysosomal storage disorder due to mutations of the <em>GAA</em> gene, leading to the deficiency of acid α-glucosidase and consequent glycogen storage in various tissues, mainly in the skeletal muscle, heart and liver. The consequent clinical picture is mainly due to the muscle and heart involvement, although clinical manifestations may be multi-systemic. The phenotype of patients is heterogeneous and the severity is inversely related to the residual enzymatic activity of acid α-glucosidase. More than 200 different mutations of <em>GAA</em> gene have been described and genotype/phenotype correlations have been established for some of them. Traditionally three forms have been described, <em>i.e. </em>early onset <em>classical</em> and <em>non-classical</em> forms and late onset attenuated forms. A severe hypertrophic cardiomyopathy in combination with conduction disorder in newborns represents a typical feature in the classic infantile presentation, while clinical picture in late onset forms is dominated by skeletal muscle dysfunction, resulting in mobility and respiratory problems. Enzyme replacement therapy with recombinant human GAA is the approved therapeutic approach in Pompe disease patients. Clinical trials on enzyme replacement therapy (ERT) support the efficacy in improving survival and hypertrophic cardiomyopathy, while efficacy seems to be variable on manifestations due to skeletal muscle involvement, mainly in lateonset patients. Considering the limitations of ERT and its high costs, innovative therapeutic approaches are now under development. |
topic |
Pompe disease, glycogen storage disease type II, acid a-glucosidase, acid maltase, metabolic myopathy. |
url |
http://www.pagepressjournals.org/index.php/cardiogen/article/view/905 |
work_keys_str_mv |
AT giancarloparenti molecularbasisandclinicalmanagementofpompedisease AT giuseppediiorio molecularbasisandclinicalmanagementofpompedisease AT simonesampaolo molecularbasisandclinicalmanagementofpompedisease AT giuseppefiorentino molecularbasisandclinicalmanagementofpompedisease AT vincenzofarina molecularbasisandclinicalmanagementofpompedisease AT simonafecarotta molecularbasisandclinicalmanagementofpompedisease AT fabiovalente molecularbasisandclinicalmanagementofpompedisease AT serenaascione molecularbasisandclinicalmanagementofpompedisease AT mariocaputi molecularbasisandclinicalmanagementofpompedisease AT generosoandria molecularbasisandclinicalmanagementofpompedisease |
_version_ |
1724356323150135296 |